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Abstract Calprotectin is member of the S-100 protein
family with a wide plethora of intra-and extracellular
functions. Anticancer activities, antimicrobial effects and
being a qualified disease marker are among the compelling
features of this protein to be used as a pharmaceutical
agent. However, there are several impediments to appli-
cations of protein pharmaceuticals including: proteolytic
degradation, short circulating half-life, low solubility and
immunogenicity. Pegylation is a common bioconjugation
polymer capable of overcoming these drawbacks. Recom-
binant expression and purification of calprotectin along
with its pegylation would result in enhanced pharmaco-
dynamic and pharmacokinetic properties. Our florescence
spectroscopy and far Ultraviolet-optical density results
indicate that pegylation altered the physical and structural
properties of the calprotectin to become in a more
stable and functionally active state. Due to enhanced
pharmacodynamic and pharmacokinetic properties of the
calprotectin via pegylation, this study would pave the way
for better in vitro and in vivo validations of calprotectin
applications in medical practice.
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Abbreviations
CD Circular dichroism
IPTG Isopropyl-thio-b-D-galactoside
mPEG Methoxy poly ethylene glychol
MRP Myeloid inhibitory factor related protein
Ni2?-NTA Nickel-nitrilotriacetic acid
PEG Polyethylene glycol
SDS PAGE Sodium dodecyl sulphate
polyacrylamide gel electrophoresis
1 Introduction
Calprotectin is a calcium- and zinc binding protein of the
S-100 protein family with a wide plethora of intra- and
extracellular functions. It plays a pivotal role in the regu-
lation of inflammatory processes and immune response.
The protein complex is a 24 kDa heterodimer, incorpo-
rating a light (MRP8 also known as RP8/S100A8/L1L/P8)
and a heavy (MRP14 MRP14 also known as S100A9/P14/
L1H) chain. Calprotectin reported to have antimicrobial
activities towards bacteria and fungi. The antimicrobial
activity most likely is exerted via the ability of calprotectin
to chelate Zn2? which is essential for microbial growth.
Moreover, it can induce cell death via autophagy and
apoptosis; it have protective role in preventing exaggerated
tissue damages; it acts as a potent amplifier of inflamma-
tion in autoimmunity as well as in cancer development and
tumor spread, while regulates cell survival, neutrophil
number and apoptosis [1–4].
The utilization of proteins and peptides as medicinal
substances become to be an inevitable part of contemporary
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biological studies. Despite of the unprecedented application
of biopharmaceuticals in prevailing medical practice, there
are still several impediments to their applications including:
proteolytic degradation, short circulating half-life, low sol-
ubility and immunogenicity. Therefore, understanding their
mechanism of action and better efficiency necessitates
additional improvements. In this regard, the covalent
derivatization of biomolecules or ‘‘Bioconjugation’’ is a
novel approach, garnering a lot of attention. Bioconjugated
molecules could be expeditiously employed for discovery of
biological interactions, rigorous biochemical analyses,
diagnosis, in vivo imaging and industrial applications [5]. In
this regard, there have been a staggering progress in
molecular altering technologies and formulation, enabling
proteins and peptides to be delivered in vivo with enhanced
pharmacodynamic and pharmacokinetic properties [6–8].
One of the well-established techniques in the field of bio-
conjugation is the conjugation of polyethyleneglycol (PEG)
molecules to proteins (commonly referred as PEGylation).
PEG is biologically inert, nontoxic, nonimmnogenic poly-
mer. The predominant use of protein PEGylation has been
associated with decreasing the immunogenicity and
increasing the biological half-life of protein drugs [9].
Creating a reactive functional group is the first step for
PEGylation of molecules. A wide variety of commercially
available chemistries have been developed for protein
PEGylation [10], most of which focused on different ways to
synthesize PEG derivatives capable of conjugating with free
amino groups to form amide bonds. This method is preferred
for most applications due to the abundance of free amino
groups in proteins (Lysine and Arginine residues) and the
stability of the formed amide bonds [11]. Using cyanuric
chloride as a coupling agent is one of the original methods of
protein derivatization with PEG molecules [12].
All of the aforementioned properties make calprotectin a
compelling therapeutic target for clinical applications.
Therefore, using a bioconjugation method like PEGylation
technique seems intriguing to decrease its proteolytic
degradation, increase its short circulating half-life and deal
with its solubility and immunogenicity. In present study PEG
conjugation technique was employed to PEGylate an
s100A8/9 complex, produced by recombinant expression and
purification. Assessing the physical and structural properties
of the PEGylated complex indicates the acquisition of a more
stable and functional state for the final complex.
2 Materials and Methods
2.1 Recombinant Vectors Harboring S100A8/A9
According to standard protocol [13], S100A8 and S100A9
sequences (ordered from Biomatik company) were sub-
cloned into pET15b vector [Novagen (EMD Millipore)]
and then transformed into E.coli BL21 (DE3) competent
cells, grown on ampicillin (100 lg/l) containing LB agar
plates. The sequences of the study are used from a human
source were previously employed in our lab in conduction
other studies [14, 15]. One of the transformed white
colonies for both S100A8 & S100A9 were selected for
confirmation by sequencing (using T7 universal primers)
and expression of recombinant protein.
2.2 Recombinant Expression of S100A8 and S100A
Transformed colonies were cultured in LB broth containing
ampicillin (100 lg/l) with concurrent shaking. Induction of
recombinant subunits (r-S100A8 and r-S100A) was done at
OD600 of 0.6 using 1 mM IPTG for 4 h at 37 C. Following
the induction, cellswere collected by centrifugation at 4200 g
for 15 min at 4 C and lysed employing sonication (the
conditions were as follow: three cycles of 20 s sonication,
30 % power and on ice), while suspended in PBS lysis buffer
(NaH2PO4 1.9 mM, Na2HPO4 8.1 mM, NaCl 154 mM,
pH = 7.2) on ice. The sonicated precipitate was centrifuged
at 12000g for 30 min at 4 C. Sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) was performed
using 12 % polyacrylamide gels according to Laemmli pro-
tocol [16]. Fifteen ll of protein solution and standard
molecular mass marker were mixed with SDS-PAGE sample
buffer and heated in boiling water for 5 min. Electrophoresis
was carried out at a constant current of 30 mA. The gel was
then stained with Coomassie Brilliant Blue R-250 (Sigma)
and incubated in de-staining solution with gentle shaking to
remove background to visualize protein bands.
2.3 Protein Purification
The cleared supernatant subjected to purification step based
on an affinity binding between His6-Tag sequence on the
recombinant S100A8 and S100A9 and Ni-NTA resins in
the column. The supernatant was loaded on to Ni-NTA
column and finally eluted with imidazole solutions from
10 mM up to 150 mM imidazole concentrations (Tris
100 mM, NaCl 25 mM, imidazole 10 mM up to 150 mM,
pH = 7.5). Eventually, imidazole was removed from
purified protein by dialysis. Dialysis was done by PBS
dialysis buffer (NaCl 25 mM, NaH2PO4 100 mM,
pH = 6.5) for 8 h at 4 C and stored at -80 C for further
analysis and SDS-PAGE.
2.4 Protein Assay and Complex Formation
of r-S100A8 and r-S100A9
The protein concentration was measured by Bradford
method [17] using Nano Drop spectrophotometer with
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bovine serum albumin as standard. To prepare r-S100A8/
A9 complex, equal volumes of r-S100A8 and r-S100A9
(1 lM each), were incubated with calcium chloride
(1 mM) in PBS dialysis buffer for at least 15 min at 25 C,
as previously described [18]. The complex formation was
investigated by fluorescence and CD spectroscopy.
2.5 Activation of mPEG33KD with Cyanoric
Chloride
The methoxy-PEG (mPEG) (5gr), 151 lM, was dried in a
vacuum desiccator for 1.5 h at 80 C, then dissolved in
40 ml anhydrous benzene and stirred for 10 min at 70 C.
Then, a combination of cyanoric chloride (33.1gr) and
anhydrouse sodium carbonate was added after 30 min. The
solution stirred for 24 h at room temperature and then fil-
tered. Thereafter, for three cycles 200 ml petroleum ether
was added gradually (solution A) and the precipitate was
dried out. The precipitate was dried in vacuum desiccator
and ultra-filtered by filter paper (solution B) to achieve
activated mPEG with cyanoric chloride (monomethyl
ether, poly ethylenglychol 4, 6 dicholoro1, 3, 5 triazin).
The produced white powder stored in -20 C.
2.6 Coupling of mPEG-triazin and Recombinant
Protein Complex
Two hundred ll of S100A8/9?Ca complex (1.9 mg/l), was
dissolved in 100 ml of 0.1 M sodium tetraborate at 3 dif-
ferent pH (6.5, 7.2 and 9.2). This solution and activated
mPEG in different ratio concentration (0.01, 0.025,
0.001 mM) were mixed at 4 C and room temperature.
After 1 h uncoupled mPEG was removed by dialysis using
PBS dialysis buffer (Nacl 25 mM, NaH2PO4 100 mM,
pH = 7.2) for 18 h according to [12].
2.7 Circular Dichroism (CD) Spectra
Recombinant S100A8/9 (r-S100A8/9) complex and
PEGylated r-S100A8/9 (mpeg- r-S100A8/9) complex were
used to assess the effects of PEGylation on structure and
proteolytic stability of these complexes, using CD spectra
and trypsin treatment. The data were recorded in dialysis
buffer (pH = 6.5) at concentration of 0.05 mg/ml and
reads were performed with 1 mm path length quartz cell at
25 C. All spectra were collected from 190 to 260 nm and
the background was corrected using the buffer as blank.
The r-S100A8/9 complex was incubated with mPEG
(0.025 mM at pH = 6.5, 7.2 and 9.2) for 1 h. To analyze
the proteolytic consequence of trypsin treatment on
S100A8/9 complex in presence and absence of mPEG
trypsin (0.01 %) was incubated with the complexes (with
1:1, 1:3 and 3:1 ratios, at pH = 7.2, for a time range
includes 10, 30 and 60 min, at room temperature). The data
were expressed as molar elipticity (deg.cm2/dmol) con-
sidering a mean residue number of 207 and average
molecular weight of 25 kDa for r-S100A8/A9 complex
[19]. The molar ellipticity was determined as
[h] = [100 9 (MRW) 9 hobs/(cl), where hobs is the
observed ellipticity in degrees at a given wavelength, c is
the length of the light path in cm [20].
2.8 Intrinsic Fluorescence Spectroscopy
The fluorescence measurements of r-S100A8/A9 complex,
following a treatment with calcium chloride (1 mM), and
PEGylated samples (0.001, 0.025 and 0.01 mM) in 50 mM
PBS buffer were performed using a Cary 100 biospec-
trofluorimeter equipped with a 150 W xenon lamp, a DR-3
data recorder and emission slits set at 5 and 10 nm [21].
Intrinsic fluorescence using cuvettes with a 1 cm path
length and with excitation wavelength of 295 nm was used
in all of these studies.
3 Results
3.1 Gene Sub-cloning
The sub-cloning of the genes was successfully confirmed
by sequencing of the resulted vectors using T7 universal
primers.
3.2 Protein Expression, Purification
and PEGylation
As depicted in Fig. 1, the protein expression of S100A8
and S100A9 resulted in overexpression of both subunits
Fig. 1 The SDS-PAGE analysis of recombinant S100A8 and S100A9
expression (1 Marker, 2 S100A8 expression (lysed bacteria), 3
S100A8 expression (the supernatant of the lysed bacteria after
centrifugation) 4 S100A9 expression (the supernatant of the lysed
bacteria after centrifugation) and 5 S100A9 expression (lysed
bacteria))
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migrating with an apparent molecular weight of about 8
and 14 kDa compared to the logarithm of molecular weight
of standard marker proteins. The protein assay results
indicate that the expression for S100A8 and S100A9 are
equal to 0.1 and 0.07 mgr/mL respectively. Moreover,
according to the electrophoresis, fractions of 100 and
150 mM concentrations of imidazole appeared to have
single and the broadest band for S100A8 and S100A9
respectively (Fig. 2). Therefore, these concentrations were
selected for protein purification. Figure 3 shows the quality
of recombinant protein preparation following dialysis
experiments. The PEGylation of the r-S100A8/9 was suc-
cessfully attempted as the next step.
3.3 Fluorescence and Far UV-CD Studies
of r-S100A8/A9 Complex
The assembly of r-S100A8 and r-S100A9 subunits to the
quaternary structure of r-S100A8/9 leads to structural
changes. The results of fluorescence and far UV-CD
showed that increasing the concentration of mPEG clearly
enhanced the intensity of r-S100A8/9 complex. The spec-
troscopic properties of mPEG- r-S100A8/9 complex with
different concentrations of mPEG are shown in Fig. 4. The
fluorescence and far UV-CD spectra indicate significant
diversity between r-S100A8/9 complex and mPEG-r-
S100A8/9 complex in different concentration of mPEG.
Figure 5 shows the effect of pH change on the bioconju-
gation yield using fluorescence and far UV-CD analyses.
Interestingly, significant differences were observed
Fig. 2 The SDS-PAGE
analysis of purification attempts
at various concentrations of
imidazole. The picture on the
left belongs to S100A8 and the
picture on the right belongs to
S100A9 (1 marker, 2
supernatant, 3 flow through, 4
50 mM, 5 75 mM, 6 100,
7.150 mM, 8 200 mM)
Fig. 3 The SDS-PAGE analysis for dialyzed S100A8 and S100A9
proteins (1 marker, 2 S100A8 expression, 3. S100A9 expression and
4. Both proteins together)
Fig. 4 The spectroscopic properties of mPEG- r-S100A8/9 complex
with different concentrations of mPEG. From top to bottom the curves
belong to florescence emission of S100A8/9 complex PEGylated in
0.01 mM mPEG, 0.025 mM mPEG, 0.001 mM mPEG and without
mPEG
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between pH 9.2, 7.2 and 6.5, where the protein is fairly
stable. As results obtaining from fluorescence and far UV-
CD analysis indicate (Fig. 6), there is an apparent differ-
ence between PEGylated protein and native form
responding to the trypsin treatment in varying concentra-
tions and duration. Table 1 lists the percentages of alpha
helixes and beta sheets of the r-S100A8/9 complex in
various conditions. Our results indicate that the PEGylation
leads to increased alpha helix and beta sheet content of the
complex.
4 Discussion
The ongoing studies on calprotectin protein elucidated
significant aspects of its biology. Anticancer activities,
antimicrobial effects and being a qualified disease marker
are among the compelling features of this protein
[19, 22–24]. However, conduction of structural and func-
tional studies as well as investigating molecular bases of
protein–protein and protein–ligand interactions would not
be feasible without an abundant source of expressed
S100A8/9 complex. Recombinant expression of calpro-
tectin is previously reported by several research groups
[25, 26]. Since Ca2? is essential to form a r-S100A8/9
complex, a sufficient source of Ca2? should be added to
have functional heterodimers of calprotectin [27, 28]. The
heterodimer assembly is energetically favorable due to
burying surface accessible regions of both S100A8 and
S100A9 proteins. Residues spanning 1–42 and 51–78
within S100A9 and residues spanning 4-45 and 59-86
within the S100A8 are actively involved in heterodimer
assembly. A unique salt bridge between Asp30 from
S100A9 and His87 and His83 from S100A8 is the main
stabilizing bond [29]. Displacement of aromatic residues
from the more hydrophobic patches of the protein onto the
surface of the complex, following the heterodimer assem-
bly, is in line with the Ca2? tendency to increase the sur-
face hydrophobicity of the proteins and protein assembly
[20].
The FDA approved the PEG molecule to be safe for
clinical uses with molecular weights of over 1000 Da [9,
30]. There are several properties for PEG molecule ren-
dering this molecule as an amenable agent to improve the
desired protein features. These properties include: 1- lack
of toxicity and high mobility, 2- lack of immunogenicity
and allergenicity, 3- flexibility and high solubility inwater
and organic solvents and 4- high hydrophilicity [30, 31].
Due to the high mobility and hydration shell of the polymer
chains, PEGylation increases the size of protein complexes
considerably more than the molecular weight increase; this
leads to slower clearance from the blood stream and lower
immunogenicity, which in turn leads to longer biological
half-lives for PEGylated drugs. Lower doses needed for
effective treatment and thus reduced systemic toxicity are
the consequences of achieved longer biological half-lives.
Furthermore, PEG has been used to modify water-soluble
proteins to solubilize them in organic solvents [9, 30, 32].
Since, protein PEGylation is endowed with bringing about
valuable properties, calprotectin PEGylation seems to be a
rational method to improve its pharmaceutical properties.
As Abuchowski et al. [12] have pointed out in their
study even PEG1900-albumin and PEG-5000-albumin do
not enter 4 % acrylamide gel duo to the their high MW.
Our PEG/protein complex is much bigger and as expected
the complex did not enter the SDS page gel. It should be
noted that in the case of PEG activation failure or protein
sedimentation, the changes in protein native structure or its
Fig. 5 Fluorescence (left) and far UV-CD (right) analyses to assess
pH effects on PEGylation yields. From top to bottom the fluorescence
curves belong to PEGylated r-S100A8/9 complex in pH = 9.2,
PEGylated complex in pH = 7.2, PEGylated complex in pH = 6.5
and nonPEGylate complex in PH = 6.5, while this order is vice versa
in UV-CD curves
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degradation would most likely occur. Our results indicated
an unchanged pattern of structural features, while the PH
was changing. On the other hands, significant changes have
been observed changing from the PH of 6.5 to the pH of 9
which is the consequence of behavioral changes of amino
acids like lysine in interaction with activated PEG. These
Fig. 6 Fluorescence (plots on the left) and far UV-CD (plots on the
right) analyses to assess trypsin effects on nonPEGylated (plots on the
top) and PEGylated (plots on the bottom) complexes by different
concentrations (plots on the left) and durations (plots on the right.
From top to bottom the fluorescence curves belong to r-S100A8/9
complex treated with no trypsin, 1:3, 1:1 and 3:1 volume ratio of
trypsin/PEGylated complexes. From top to bottom the UV-CD curves
belong to r-S100A8/9 complex treated with trypsin for 60 min,
trypsin for 30 min, trypsin for 10 min and no trypsin for both
PEGylate and nonPEGylated complexes
Table 1 The structural
composition of r-S100A8/A9 in
different conditions (numbers
are in percent of whole protein
and all the reactions are in
presence of Ca2?)
Proteins a-Helix (%) b-Sheet (%) Other structures (%)
S100A8/A9 ? PEG PH = 6.5 41.4 21.1 37.5
S100A8/A9 ? PEG PH = 7.2 44.6 18.2 37.2
S100A8/A9 ? PEG PH = 9.2 52.8 17.3 29.9
S100A8/A9 ? PEG ? Trypsin0.01 % 10 min 35.8 22.5 41.7
S100A8/A9 ? PEG ? Trypsin0.01 % 30 min 32.4 23.2 44.4
S100A8/A9 ? PEG ? Trypsin0.01 % 60 min 31.8 23.7 44.5
S100A8/A9 ? Trypsin0.01 % 10 min 31.2 21.9 46.9
S100A8/A9 ? Trypsin0.01 % 30 min 27.8 21.1 51.1
S100A8/A9 ? Trypsin0.01 % 60 min 27.1 20.6 52.3
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changes are well documented in several studies [33–35].
Moreover, the presence of cyanoric chloride in the solution
A (yellow) and its absence in the solution B (blue)
apparently indicates chloride binding to PEG molecules
and its activation. The PEG and r-S100A8/9 complex
interactions are highly pH dependent [36]. Our results
confirmed that increasing the pH, changes the amino acids
behavior, leading to an increase in florescence emission
and a shift into left in its diagram as a consequence of more
amenable PEGylation. This would be rooted in the change
of the histidine residue behavior at pH C 7 and the pre-
liminary role played by the epsilon-amino group of lysines
at pH = 9.2. Moreover, the N terminal alpha amino groups
of amino acids which are less active in comparison to
lysine establish more stable interactions with PEG mono-
mers by reaching more basic pH [37].
It has been demonstrated that the relative amount of
alpha helixes and beta sheets of proteins is physiologically
significant and this relative proportion could be changed in
the case of some disease [20, 38–40]. This kind of struc-
tural changes and aromatic residues movement onto the
surface of the complex are crucial implementing some of
the calprotectin protein functions including: inhibition of
the casein function and apoptosis induction [20, 41, 42].
Our far UV-CD analysis indicates that the subunits of
calprotectin have a high content of alpha helixes [20].
Although, the presence of Ca2? decreases the alpha helix
content, the overall Ca2? changes are negligible. However,
as revealed by our analysis pH changes have more serious
impact on the content of alpha helixes, could be important
exerting various functions of calprotectin. Since, the cal-
protectin is a member of S-100 protein family, known for
the pivotal roles of abundant alpha helixes in their structure
and function, PEGylation originated increase in alpha
helixes would help their structural integrity and stability.
The maximum lambda of the florescence emission plot
depends on the pH and the concentration of mPEG. In this
regard, our results indicate that increasing the pH and the
concentration of mPEG would lead to a decrease in max-
imum of the wave length or the blue shift.
Trypsin is a commonly used endopeptidase (a serine
protease) capable of cleaving the proteins into polypep-
tides. Use of trypsin to analyze its proteolytic activity on
deferent proteins is wide spread. Lysine and arginine
residues are among the hot spots of trypsin function. Cal-
protectin contains numerous lysine residues some of which
are located in surface accessible regions. The PEGylation
related interactions mainly occur at locations of lysine
residues. Preoccupation of these lysine residues by PEG
molecules restricts trypsin access to the protein, therefore
inhibits the trypsin function in different concentration and
time periods of treatment. It could be apparently deduced
that the calprotectin PEGylation increases the protein
stability and half-life masking its surface in protease ten-
sions. Given the maximum lambda of the florescence
emission plot which is a direct consequence of the trypsin
activity, it could be deduced that the increase in trypsin
concentration would lead to an increase in maximum of the
wave length or the red shift.
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